19 December 2016 - Vertex Pharmaceuticals today announced it has reached a pricing and reimbursement agreement for Orkambi (lumacaftor with ivacaftor) with the German Federal Association of the Statutory Health Insurances. 

Orkambi is the first medicine to treat the underlying cause of cystic fibrosis in people ages 12 and older who have two copies of the F508del mutation in the CF transmembrane conductance regulator gene.

Today’s announcement follows a comprehensive benefit assessment of the medicine by the G-BA, which recognised the “considerable additional benefit” of Orkambi for people with cystic fibrosis who have two copies of the F508del mutation. 

Orkambi has been available to eligible patients in Germany since it was granted marketing authorisation from the European Commission in November 2015, and the reimbursement agreement announced today took effect on December 16, 2016.

Read Vertex Pharmaceuticals press release